lenalidomide has been researched along with Debility in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahlis, NJ; Basu, S; Belhadj-Merzoug, K; Benboubker, L; Caillot, D; Cook, G; Decaux, O; Facon, T; Goldschmidt, H; Hebraud, B; Hulin, C; Kobos, R; Kumar, S; Manier, S; Mohty, M; Nahi, H; Pei, H; Plesner, T; Quach, H; Raje, N; Touzeau, C; Uhlar, CM; Ukropec, J; Usmani, SZ; Van Rampelbergh, R; Venner, CP; Weisel, K; Zweegman, S | 1 |
| Chen, L; Djebbari, F; Ellis, L; Eyre, TA; Gomes, AR; Gray, N; Khera, A; Kothari, J; Lees, C; Lim, WY; Moore, S; Panitsas, F; Prideaux, S; Prodger, C; Ramasamy, K; Rampotas, A; Sangha, G; Tsagkaraki, I | 1 |
| Best, P; Bird, J; Bowcock, S; Boyd, K; Cairns, DA; Cook, G; Coulson, AB; Dawkins, B; de Tute, R; Drayson, M; Gardner, H; Henderson, R; Hockaday, A; Jackson, G; Jenner, M; Jones, J; Kaiser, M; Kishore, B; Meads, D; Olivier, C; Owen, R; Parrish, C; Pawlyn, C; Rabin, N; Royle, KL | 1 |
| Abel, GA; Bihn, J; Brophy, M; Corrigan, J; Dharne, M; Do, NV; Driver, JA; DuMontier, C; Fillmore, NR; Gaziano, JM; Hassan, H; Kim, DH; La, J; Munshi, NC; Yellapragada, S; Yildirim, C | 1 |
| Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E | 1 |
| Brioli, A; Fabisch, C; Hänel, M; Hochhaus, A; Illmer, T; Knop, S; Krammer-Steiner, B; Manz, K; Mügge, LO; Pfirrmann, M; Prange-Krex, G; Schwarzer, AC; von Lilienfeld-Toal, M | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Bang, SM; Do, YR; Eom, HS; Jo, JC; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Lee, Y; Lim, SN; Min, CK; Mun, YC; Park, SK; Park, Y; Shin, HJ; Yi, JH; Yoon, DH; Yoon, SS | 1 |
6 trial(s) available for lenalidomide and Debility
| Article | Year |
|---|---|
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Frailty; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2022 |
Topics: Aged; Clinical Trials, Phase III as Topic; Frailty; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Quality of Life; Randomized Controlled Trials as Topic; United Kingdom | 2022 |
More intensive therapy has a better effect for frail parents with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Frail Elderly; Frailty; Humans; Lenalidomide; Multiple Myeloma | 2023 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Double-Blind Method; Female; Frail Elderly; Frailty; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisolone; Progression-Free Survival | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
2 other study(ies) available for lenalidomide and Debility
| Article | Year |
|---|---|
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Frailty; Humans; Lenalidomide; Male; Models, Statistical; Multiple Myeloma; Prognosis; Retrospective Studies; Survival Rate; United Kingdom | 2022 |
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Aged; Aged, 80 and over; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Frailty; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Failure; Treatment Outcome | 2021 |